首页> 中文期刊> 《基层医学论坛》 >螺内酯联合福辛普利治疗慢性心力衰竭疗效研究

螺内酯联合福辛普利治疗慢性心力衰竭疗效研究

             

摘要

ObjectiveTo study the curative effect of treating chronic systolic heart failure by using spironolactone combined with Fosinopril.Methods94 cases of chronic heart failure patients,were randomly divided into control group (n=48 cases)and treatment group(n=46 cases). Besides using Diuretic and Beta Blockers as usual,the treatment group added spironolactone Tablets and Fosinopril and observed the patients for 1 years. Then compared left ventricular diastolic diameter(LVDd),left ventricular ejection fraction(LVEF).ResultsThe ultrasonic indicators of the treated patients in these two groups got improved,but their Left ventricular end-diastolic diameter of the patients in the treatment group were reduced more greatly,their left ventricular ejection fraction were risen,but there were statistically significant difference(P<0.01).ConclusionThe treatment by using spironolactone tablets combined with fosinopril to treat chronic systolic heart failure can control left ventricular remodeling,improve cardiac function.%目的:研究螺内酯联合福辛普利治疗慢性收缩性心力衰竭的疗效。方法选取94例慢性心力衰竭患者,随机分为对照组(n=48例)和治疗组(n=46例),常规使用利尿剂、β受体阻滞剂,治疗组加用福辛普利和螺内酯,观察时间1年。对比治疗前后左心室舒张末期内径(LVDd)、左心室射血分数(LVEF)。结果2组治疗后超声指标均得到改善,治疗组LVDd缩小、LVEF提高程度均显著优于对照组(P<0.01)。结论螺内酯联合福辛普利能抑制慢性心力衰竭患者的左室重构,提高心功能。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号